The Heterogeneity of Liver Cancer Metabolism

Javier Salazar, Anne Le

Research output: Chapter in Book/Report/Conference proceedingChapter


Primary liver cancer is the fourth leading cause of cancer death around the world. Histologically, it can be divided into two major groups, hepatocellular carcinoma (75% of all liver cancer) and intrahepatic cholangiocarcinoma (15% of all liver cancer) [1, 2]. Primary liver cancer usually happens in liver disease or cirrhosis patients [1], and the risk factors for developing HCC depend on the etiology [3] and the country of provenance [1]. There is an urgent need for an accurate diagnostic test given the high proportion of false positives and false negatives for alpha-fetoprotein (AFP), a common HCC biomarker [4]. Due to often being diagnosed in advanced stages, HCCrelated deaths per year have doubled since 1999 [3]. With the use of metabolomics technologies [5], the aberrant metabolism characteristics of cancer tissues can be discovered and exploited for the new biomarkers and new therapies to treat HCC [6, 7].

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
Number of pages10
StatePublished - 2021

Publication series

NameAdvances in Experimental Medicine and Biology
ISSN (Print)0065-2598
ISSN (Electronic)2214-8019


  • Glucose metabolism
  • Glutamine metabolism
  • Lipid metabolism
  • Metabolic phenotypes
  • Oncogenic heterogeneity
  • Primary liver cancer
  • Redox metabolism
  • Sorafenib

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'The Heterogeneity of Liver Cancer Metabolism'. Together they form a unique fingerprint.

Cite this